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Methods
Patients (pts) were selected from the Dat’AIDS French
prospective cohort if they were prescribed an ABC/3TC
containing regimen for the first time between 01/01/
2004 and 31/12/2007 and were still actively followed on
31/05/2008 as to ensure sufficient follow-up. All causes
of treatment discontinuation were recorded, as well as
immuno-virological data and cardiovascular events (CE)
during follow-up.
Results
Among the 1704 pts included in the study (male 70%,
mean age 43 years, HBV or HCV co-infection 24.1%)
407 (24%) were antiretroviral (ARV) naïve, 696 (41%)
were virologically controlled on ARV treatment (switch),
and 601 (35%) were on treatment with detectable VL
(failure) at time of ABC/3TC initiation. Previous treat-
ment with 3TC was noted in 92% of the pretreated pts.
With a median duration of follow-up of 496 days, the
population represents 2636 pts-year.
Overall 565pts (33%) discontinued ABC/3TC combi-
nation during follow-up (36%, 24%, and 42% of the
naive, switch and failure groups, respectively). Reasons
for discontinuation were poor tolerance in 41% of the
cases, including suspected hypersensitivity (HSR) in 4%
of the overall population, treatment failure in 20%, and
other causes in 39%. This distribution was not different
if pts received either a NNRTI (20% of the pts) or a
boosted protease inhibitor (46%) in their regimen.
Median time to discontinuation was 4.3 years overall
and less than one month in case of suspected HSR.
Discontinuation for bad tolerance was observed in
38%, 54%, and 35% of the naïve, switch and failure
populations respectively, whereas treatment failure was
responsible for discontinua t i o ni n1 5 % ,1 0 % ,a n d2 9 %
of the same populations. Major CE were reported in
21 cases (0.08% py). Death was recorded in 27 cases, 9
deaths being AIDS related, 6 related to liver diseases, 6
to cancer, 2 to vascular accidents (1 cardiac, 1 neuro-
logical), 1 accidental, and 3 unknown. At M24, prob-
ability of still receiving ABC/3TC was 62%, 77%, and
60% respectively for the defined groups, and VL on
treatment was below detection for 86%, 90%, and 71%
of them, respectively.
Conclusion
In this population of pts who received ABC/3TC con-
taining regimens before HLA screening was routinely
available, treatment was maintained with virological suc-
cess for more than 2 years. Poor tolerance was the main
reason for early discontinuation, and was not different if
the pts received either NNRTI or boosted PI in their
regimen. CE were rare.
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